Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease

Author： Kato T.   Tokoro T.   Namii Y.   Kobayashi T.   Hayashi S.   Yokoyama I.   Morimoto S.   Chan M.   Giannetti N.   Hunt S.A.  

Publisher： Elsevier

ISSN： 0041-1345

Source： Transplantation Proceedings, Vol.32, Iss.2, 2000-03, pp. : 331-333

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine

By Rodrguez J.A.   Crespo-Leiro M.G.   Paniagua M.J.   Cuenca J.J.   Hermida L.F.   Juffe A.   Castro-Beiras A.  

Transplantation Proceedings, Vol. 31, Iss. 6, 1999-09 ,pp. : 2522-2523

Elsevier

Access to resources Recommend Favorite

Effect of HMG-CoA reductase inhibitors on reduction of panel reactivity

By Ossareh S.   Ghorbani G.   Ghods A.J.  

Transplantation Proceedings, Vol. 35, Iss. 7, 2003-11 ,pp. : 2592-2593

Elsevier

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors Pravastatin and Simvastatin Inhibit Human B-Lymphocyte Activation

By Rudich S.M.   Mongini P.K.A.   Perez R.V.   Katznelson S.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 992-995

Elsevier

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol

By  

Current Drug Targets - Cardiovascular & Hematological Disorders, Vol. 5, Iss. 6, 2005-12 ,pp. : 441-453

Bentham Science Publishers

Access to resources Recommend Favorite

Microvascular prothrombogenicity and transplant coronary artery disease

By Labarrere C.A.   Deng M.C.  

Transplant Immunology, Vol. 9, Iss. 2, 2002-05 ,pp. : 243-249

Elsevier

Access to resources Recommend Favorite